Modeled data shows non-opioid acute pain treatment and opioid reduction decreases hospital stay, potential opioid-related complications, costs for surgical patients

New health economic data from a retrospective analysis suggests use of OFIRMEV® (acetaminophen) injection, coupled with a one-level reduction in opioid use (high to medium, medium to low, or low to none), was associated with decreased length of hospital stay, potential opioid-related complications and related costs for the treatment of acute surgical pain. The study, which evaluated data from The Advisory Board Company’s database of more than 2.2 million anonymous adult (age 18 and older) inpatient surgical admissions across 297 U.S. hospitals from 2012 to 2014, was presented as a moderated ePoster last week at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting in New Orleans.

Advertisement

This analysis may provide important insight for surgeons, pharmacists and hospital administrators looking for possible ways to help improve patient outcomes and provide savings to the hospital system. The use of opioids alone has been a mainstay for acute pain management. There is an overreliance on opioids as monotherapy to treat acute pain in U.S. hospitals today and 7 out of 10 hospital patients treated with intravenous (IV) analgesia receive IV opioids alone. These results suggest that a multimodal analgesia approach to pain management with OFIRMEV, combined with a reduction in dosing levels of opioids, may contribute to reduced costs and improved outcomes for surgical patients.

To learn more, please click here.

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Patient Safety & Outcomes

Advertisement

Comments are closed.